Detection of extended spectrum-beta lactamase enzymes producing E. coli that isolated from urine

Adnan kreem Al-salamy
College of Pharmacy, University of Kufa

Abstract:
The production of extended-spectrum-β-lactamases (ESBLs) is an important mechanism for resistance to the third-generation cephalosporins. ESBLs represent a major group of lactamases enzymes that mostly produced by gram-negative bacteria, so the detection of these enzymes are very important for optimal patients care. The present study was done to detect extended spectrum beta lactamase producing E. coli among urinary tract infected patients. A total of 223 urine samples were examined for presence of E. coli and those producing ESBL enzymes. Urine samples were cultured for aerobic bacteria and antimicrobial susceptibility testing carried out by using Kirby-Baur agar diffusion method. Coli were tested for ESBLs on Mueller-Hinton agar by both modified double disk (MDDT) and phenotypic confirmatory test. E. coli was the most common bacteria isolated from urine 104 (44.2).78 E. coli isolated from urine are tested for ESBL production and it was found that 30 (38.4) were MDDT positive and 27 phenotypic confirmatory test positive. Three strain E. coli were MDDT positive but negative by phenotypic confirmatory. Antibiotic susceptibility test showed that E. coli isolated were totally resist (100%) to ampicillin, moxicillin,and trimethoprim but maximum susceptible to imipenem (100%) and variable resistant to another antibiotics. The ESBLs producing E. coli are highly resist to different types of antibiotics, especially third generation cephalosporins.

Escherichia Coli تحديد العزلات المنتجة لإنزيمات بيتا لاكتاماسات الطيف الـβ المزعولة منeductrور

عدنان كريم عبد
كلية الصيدلة، جامعة الكوفة

الخلاصة:

الإنزيمات المنتجة لـ β-lactamases(β-لاكتامازات) من الطيف الأول (β-lactamases) من الميكانيكية المقاومة المهمة للجيل الثالث. يعد إنتاج إنزيمات β-lactamases من السالفوسفورين. هذه الإنزيمات تمثل مجموعة رئيسية من إنزيمات β-lactamases المشخصة في عدد كبير من بلدان العالم والتي تنتج بشكل رئيسي من قبل البكتيريا السالبة لصبغة كرام. فالتعرف على هذه الإنزيمات مهم جداً لتوفر عناية مثلى للمرضى. تهدف الدراسة الحالية لتحديد إنزيمات β-lactamases (E. coli) واسعة الطيف المنتجة من قبل بكتيريا القولون المعزولة من المرضى.
Introduction:

Extended spectrum beta lactamase (ESBLs) enzymes were first reported in Germany in 1983 from Klebsiella pneumonia and they are group of enzymes capable of hydrolyzing the third generation oxyminocephalosporins such as (cefotaxime, ceftazidime, ceftriaxone), the monobactam (aztreonam) but not the cephemacin (cefoxitin,cefotetam) or carbapenems(imipenem,meropenem) \(^1,2,3,4\). ESBLs produced mostly by members of Enterobacteriaceae have emerged as serious nosocomial pathogens globally.\(^5,6\) The persistent exposure of bacterial strains to beta-lactams induces mutation and continuous production of beta-lactamases in these bacteria, expanding their activity even against the third and fourth generation cephalosporins such as ceftazidime, cefotaxime and cefepime and against monobactams e.g. aztreonam. Thus these new beta-lactamases are called extended spectrum beta-lactamases (ESBLs), which are mostly plasmid mediated enzymes.\(^7\) Although ESBLs have been reported more frequently from Klebsiella pneumoniae and E. coli but other members of Enterobacteriaceae and Pseudomonas spp. are also implicated for ESBL production.\(^7,8\).

There are various reports of ESBL producing organisms worldwide from hospitals environments, patients, farm animals, sewages, food material.\(^9,10,11\). Organisms producing ESBLs are clinically relevant and remain an important cause for failure of therapy with cephalosporins and other classes of antibiotics throughout the world.\(^1\) Therefore it is necessary to know the...
ESBL status of clinical isolates especially in tertiary care hospitals.

The spread of ESBLs in Gram-negative bacteria represents a major challenge to the antimicrobial therapy of infections caused by these organisms either in hospitals or in a community setting.\textsuperscript{7} While definitive guidelines for the management of patients infected with ESBL-producing bacteria are still awaited, there is strong evidence that failure to detect ESBL-mediated resistance can lead to treatment failure.\textsuperscript{12} ESBLs have serine at their active sites which attack the amide bond in the lactam ring of antibiotics causing their hydrolysis. These enzymes which now number more than 150 were initially limited to Escherichia coli and \textit{Klebsiella} species. Lately many have been spreading and are engulfing other genera specially \textit{Enterobacter} and \textit{Proteus}. ESBL phenotypes and detection have become more complex due to the diversity of the enzymes produced, emergence of inhibitor resistant ESBL variants plasmid borne resistance genes, Concurrent Amp-C production enzyme hyper production and porin loss. During the last decade a number of ESBL phenotype has been reported. The production of multiple enzymes, inhibitor resistant ESBL variant, emergence of CTX-M types of ESBLs, plasmid borne AmpC and production of ESBLs in AmpC producing strain, has rendered more complexity to the ESBL phenotypes.\textsuperscript{13} During the late 1990s and early 2000s CTX-M producing enterobacteriacea has emerged as the most common ESBL type in many parts of the world including Africa, South America, Asia and some parts of Europe.\textsuperscript{14,15}

In recent years there has been an increased incidence and prevalence of ESBLs, majority are derived from the widespread broad-spectrum β-lactamases TEM-1, TEM-2 and SHV-1. There are also new families of ESBLs, including the CTX-M and OXA-type enzymes as well as novel, unrelated β-lactamases.\textsuperscript{3} Several different methods like disk approximation or double disk synergy, modified double disc test (MDDT), NCCLs phenotypic confirmatory method, E-test ESBL strips, three dimensional test, Vitek system etc. have been suggested for the detection of ESBLs in clinical isolates.\textsuperscript{16} While each of the tests has merit, none of the tests is able to detect all of the ESBLs encountered. Disk approximation or double disk synergy is one of the currently available and widely practiced techniques for the detection of ESBLs. Phenotypic tests (double-disk synergy test, ESBL E-test, and the combination disk method) are based on clavulanate inhibition and extended spectrum of cephalosporin (ESC) susceptibility testing. They often need slight changes by either reducing the distance between the disks of ESC and clavulanate.\textsuperscript{17,18} Up till now, there is no gold standard method for ESBL detection but
NCCLS recommend the phenotypic method as confirmatory test.\textsuperscript{19}

**Materials and methods:**

**Methodology**

*Patients:* The study included collected and examined 223 urine samples from suspected patients with urinary tract infections, admitted in Al- Sader medical city.

*Culture and Antimicrobial susceptibility testing:* Following aseptic collection, urine samples were inoculated onto Blood agar and MacConkey agar media. The plates were incubated at 37°C aerobically and after overnight incubation, they were checked for bacterial growth. All organisms were identified by their colony morphology, staining characters, pigment production, motility and other relevant biochemical tests as per standard methods of identification\textsuperscript{20}. All gram-negative bacteria isolates were tested for antimicrobial susceptibility by using commercially available antimicrobial discs on Mueller Hinton agar\textsuperscript{19}. *E. coli,* were tested against ampicillin (30μg), cotrimoxazole (30μg), gentamicin ((30μg), ciprofloxacin (10μg), aztreonam (30μg), ceftriaxone(30μg), ceftazidime (30μg),amikacin(30μg),amoxicillin(25μg),and imipenem (30μg). Zone of inhibition was recorded as *Sensitive* or *Resistant* according to NCCLS chart.\textsuperscript{21}

**ESBLs detection**

*Modified double disc test (MDDT)*\textsuperscript{18}

**Phenotypic determination of ESBL enzymes**

ESBL detection was determined isolated bacteria namely *E. coli* using double disc synergy test. Briefly, a sterile Mueller-Hinton agar was prepared and a 0.5 MacFarland equivalent standard of the test organisms was streaked on the surface of the agar with a sterile loop and allowed for 15-20 mins to pre-diffuse. An Augmentin which is a combination of clavulanic acid 20 (μg) and amoxicillin (10 μg) was placed at the center of the petri-dish and cefotaxime (30 μg), ceftaxidime (30 μg), aztreonam (30 μg) ciprofloxacin (30 μg) were placed15mm apart center to centre on the plates with a sterile forceps. These were incubated at 35°C for 18-24 h. An enhanced zone of inhibition from 5 mm above in the presence of Augmentin is regarded as positive for phenotypic production of ESBL enzyme.

**Phenotypic confirmatory test for ESBLs**\textsuperscript{19}

Confirmation of ESBL-producing isolates (MDDTpositive) was done by inhibitor potentiated disc diffusion test according to NCCLS recommendation.Combinations of ceftazidime and cefotaxime disc with lavulanic acid (10mg) were prepared an hour before their application to the Mueller Hinton plates inoculated with test bacteria (corresponding to 0.5 McFarland tube). Ceftazidime and cefotaxime
discs without clavulanic acid were placed on one side of inoculated plate and ceftazidime, cefotaxime discs combined with clavulanic acid were placed on other side of plate. Diameter of zone of inhibition was measured after overnight incubation at 37°C. A >5mm increase in a zone diameter for cefotaxime and ceftazidime tested in combination with clavulanic acid versus its zone when cefotaxime and ceftazidime were tested alone confirmed an ESBL producing organism.

**Antibiotic susceptibility studies**

Sensitivity of *E. coli* to different classes of antibiotics was performed by disc diffusion method. Briefly, a sterile Mueller-Hinton agar was prepared and a 0.5 MacFarland equivalent standard of the test organisms was streaked on the surface of the agar and allowed for 15-20 mins to pre-diffuse. The following antibiotics disc, ampicillin (30μg), cotrimoxazole (30μg), gentamicin ((30μg), ciprofloxacin (10μg), aztreonam (30μg), ceftriaxone (30μg), ceftazidime (30μg),amikacin(30μg),amoxicillin(25μg), and imipenem (30μg). were placed on the surface of the agar with a sterile forceps. These were incubated at 35°C for 18-24 h, after which the inhibition zone diameter in (mm) was taken.

**Results:**

A total of 235 urine samples were examine for presence of *E. coli* and those producing ESBL enzymes. *E.coli* was the most common organisms isolated from urine 104 (44.2 ).

Out of 78 *E. coli* isolated from urine(re tested for ESBL production and it was found that 30 ( 38.4 ) were MDDT positive and 27 phenotypic confirmatory test positive. Three strain of *E.coli* were MDDT. positive but negative by phenotypic confirmatory test. Table (2 ).

Antibiotic susceptibility studies of ESBL bacteria showed that *E.coli* isolated were totally(100%)resistant to ampicillin,amoxicillin and trimethoprim but the ESBL producing E.coli showed maximum susceptibility to imipenem(100 %) followed by amikacin(83.33%)and variably resistant to gentamicin(86.33%),ciprofloxacin(8 3.33% ),ceftriaxone ( 80% ),cefazidem (70 % ),and aztronom (60 % ).
Table (I) Frequency of ESBL among *E. coli* that isolated from urine.

<table>
<thead>
<tr>
<th>Organism</th>
<th>Urine n=235</th>
<th>Total.</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>E. coli</em> (%)</td>
<td>Male</td>
<td>Female</td>
</tr>
<tr>
<td></td>
<td>29 (27.8)</td>
<td>75 (72.1)</td>
</tr>
<tr>
<td>No. of isolated tested</td>
<td>Male</td>
<td>Female</td>
</tr>
<tr>
<td>No. of ESBL producers (%)</td>
<td>Male</td>
<td>Female</td>
</tr>
</tbody>
</table>

Table (II). Comparative of modified double disk test (MDDT) and phenotypic confirmatory method for ESBL detection

<table>
<thead>
<tr>
<th>Bacteria</th>
<th>MDDT positive</th>
<th>phenotypic confirmatory test positive.</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>E. coli</em> (No. of ESBL producers= (30))</td>
<td>30</td>
<td>27</td>
</tr>
</tbody>
</table>
Figure 1. MDDT of ESBL producing *E. coli*. Enhancement of zone of inhibition produced by susceptible strain of *E. coli* to 3rd generation cephalosporins and aztreonam towards amoxyclov disc placed at the centre.

Figure-2. Phenotypic confirmatory method for ESBL producing *E. coli*. Confirmed with ceftazidime-clavulanate (a) versus ceftazidime alone (b).

Figure-3. Phenotypic confirmatory method for ESBL producing *E. coli*. Confirmed with cefotaxime-clavulanate (a) versus cefotaxime alone (b).
Table (3). Antibiotic resistant patterns of ESBL producing *E.coli*.

<table>
<thead>
<tr>
<th>Antibiotics</th>
<th><em>E.coli</em>.n=30 (%)</th>
<th>resistant</th>
<th>intermittent</th>
<th>sensitive</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ampicillin</td>
<td>30(100)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Amoxicillin</td>
<td>30(100)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Trimethoprim</td>
<td>27(90)</td>
<td>1(3.33)</td>
<td>2(6.66)</td>
<td></td>
</tr>
<tr>
<td>Gentamicin</td>
<td>26(86.33)</td>
<td>1(3.33)</td>
<td>3(10)</td>
<td></td>
</tr>
<tr>
<td>Amikacin</td>
<td>3(10)</td>
<td>2(6.66)</td>
<td>25(83.33)</td>
<td></td>
</tr>
<tr>
<td>Imipenem</td>
<td>0(0)</td>
<td>-</td>
<td>30(100)</td>
<td></td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>25(83.33)</td>
<td>1(3.33)</td>
<td>4(13.33)</td>
<td></td>
</tr>
<tr>
<td>Ceftriaxon</td>
<td>24(80)</td>
<td>3(10)</td>
<td>3(10)</td>
<td></td>
</tr>
<tr>
<td>Ceftazidem</td>
<td>21(70)</td>
<td>2(6.66)</td>
<td>7(23.33)</td>
<td></td>
</tr>
<tr>
<td>Aztreonam</td>
<td>18(60)</td>
<td>2(6.66)</td>
<td>10(33.33)</td>
<td></td>
</tr>
</tbody>
</table>

Discussion:
In most instance, empirical antibiotics therapy of serious bacterial infection are one of the third cephalosporins, but in the last two decades, ESBL has emerged as a major contributor of cephalosporin resistant spread of ESBLs in Gram-negative bacteria represent a major challenge to the antimicrobial therapy of infection caused by these microorganisms either in hospital or in community. In the detection of ESBL-producing strains is very importance for all major hospitals worldwide, for a number of reasons, First, these strains are most likely to be even more prevalent than it is currently recognized. Due to the difficulty in their detection by the current clinical methods, many of these strains have been reported to be susceptible to widely used and tested broad-spectrum β-lactams. Secondly, ESBLs constitute a serious threat to current β-lactam therapy. Treatment of ESBL infection is difficult as the CLSI recommends that all expanded spectrum cephalosporins be taken resistant in ESBL producers. Thirdly, institutional outbreaks are increasing because of selective pressure due to the heavy use of expanded-spectrum cephalosporins and also due to lapses in effective infection control measures. Recent studies on ESBL production among the members of Enterobacteriaceae which were isolated from clinical specimens, showed an increase in the occurrence of ESBL producers. A study from North India on uropathogens such as *Klebsiella pneumoniae*, *Escherichia coli*, *Enterobacter*, *Proteus* and *Citrobacter spp.* showed that 26.6% of the isolates were ESBL producers. A study from Nagpur showed that 48.3% of their cefotaxime resistant gram negative bacilli were ESBL producers.
A report from Coimbatore (India) showed that ESBL production was 41% in E. coli and 40% in K. pneumoniae.\(^{26}\) In the present study, we also observed that 30 (38.4%) of the E. coli isolates were ESBL producers. In similar study by Haque and Salam\(^{27}\), 43.9% of the E. coli isolates were reported to be ESBL producer, also Umadevi et al\(^{28}\) showed that 47.83% of E. coli to be ESBL-producer, but Mathur et al\(^{29}\) 62% of the E. coli isolates were reported to be ESBL producer. However, ESBLs are widespread over the world but showed that, but the prevalence and phenotypic characteristics among clinical isolates may vary between geographic areas.\(^{7}\)

In our study, antibiotics susceptibility test showed that ESBLs producing E. coli isolates were 100% sensitive only to Imipenem, while showed significantly increasing multi-resistant to all other antibiotic used (table -3). Rare use of Imipenem may be explain high susceptibility to this antibiotic. However, other studies of Subha et al\(^{30}\) and Rodrigues et al\(^{31}\) showed ESBL-producing E. coli to be having the highest susceptibility to Meropenem (94.4%).

In conclusion, the ESBL E. coli are multidrug resistant so, it may be represent a major problem in the area of infection disease. To help the physician in describe the proper antibiotic in such cases, it is essential to report ESBL production along with routine sensitivity reporting. The best antibiotics can be describe for ESBL bacteria are imipenem or meropenem.

**References:**


.pneumoniae isolates from 24 U.S.
hospitals. Antimicrob Agents

7. Paterson DL, Bonomo RA.

8. Paterson DL. The epidemiological
profile of infections with multidrug-
resistant Pseudomonas aeruginosa and Acinetobacter species. Clin

production among Escherichia coli


Von Gottberg, J. M. Casellas, L. Mulazimoglu, K. P. Klugman, R. A.


30. A. Subha, S. Ananthan